You just read:

Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting

News provided by

Neurocrine Biosciences, Inc.

May 05, 2019, 09:05 ET